Key Highlights

  • Mirion Technologies (NYSE:MIR) rose 3.39% pre-market to a listed USD 16.25 on 699 shares, with a market capitalization of USD 4.05 billion and an RSI of 55.6 labeled Up.
  • Mirion reported second-quarter revenue of USD 266.8 million, up 19.7% with about 18 points from acquisitions, and organic growth of only 1.2%.
  • Backlog reached about USD 1.14 billion, up 39%, with nuclear power at 63% of backlog, and orders rose 40% to USD 291 million including acquisitions.
  • Management kept 2026 guidance of 22% to 24% total growth and 5% to 7% organic growth, while the stock rose 3.39% on only 699 shares.

The Latest Verified Updates

No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Mirion reported second-quarter 2026 results on July 28, with revenue of USD 266.8 million, adjusted EBITDA of USD 65.3 million, up 27.5%, and adjusted EPS of USD 0.12 versus USD 0.11. The shares fell after the report because organic revenue growth was only 1.2% and the Medical segment stayed weak, even as the company reaffirmed guidance. Management said first-half results plus backlog expected to convert in the second half cover about 81% of the midpoint of full-year revenue guidance.

The Data Behind the Move

Backlog was about USD 1,139 million, up 39%, or 17% excluding the Paragon and Certrec acquisitions, with nuclear power orders making up 63% of the total. Guidance calls for total growth of 22% to 24% and organic growth of 5% to 7%, which implies at least mid-teens organic growth in the fourth quarter for Nuclear and Safety. GAAP net income was USD 8.1 million, or USD 0.03 per share, and adjusted free cash flow was USD 49 million. If the listed price is the pre-market quote, simple arithmetic puts the prior close near USD 15.72; if it is the last close, the implied pre-market price is near USD 16.80, so check a live quote. Pre-market traded value is only about USD 0.01 million, a tiny slice of the company's size, so few dollars set the price. Volume of 699 shares is very thin, under 1,000 shares, and the screener tag reads No catalyst found, which classifies the catalyst and does not set direction.

Risks and What to Watch

The second-half ramp must deliver, Medical remains soft and the stock traded on only 699 shares pre-market. What to watch next: third-quarter organic growth and nuclear power orders. This is information only and not investment advice. Futures were muted on Tuesday morning with JPMorgan, Wells Fargo, Goldman Sachs and Citigroup reporting before the bell, and JPMorgan's EPS of USD 5.57 missed a USD 5.90 forecast before the stock recovered. South Korea's Kospi fell 5.5% on memory valuation concerns and China competition, Nasdaq 100 futures were down about 0.5%, and S&P 500 third-quarter earnings are expected to grow 30.6%.

Where Things Stand

Market conditions frame the day: futures were muted as big banks report, the Kospi fell 5.5% and chip and memory stocks were under pressure. Mirion Technologies (NYSE:MIR) is moving with a record backlog against slow organic growth. A pre-market gain on this volume can reverse once regular trading opens, so the balance of evidence favors waiting for confirmation from filings and the open. Direction remains unknown, and the next catalyst is third-quarter organic growth and nuclear power orders. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.